{"paper_id":"1fe00b43-5d8c-4ffa-8f23-5d9fc3e12433","body_text":"Clin Chem Lab Med 2011;49(12):2081–2088 /H170502011 by Walter de Gruyter • Berlin • Boston. DOI 10.1515/CCLM.2011.709\n2011/0242\nArticle in press - uncorrected proof\nThe diagnostic accuracy of two human epididymis protein\n4 (HE4) testing systems in combination with CA125 in the\ndifferential diagnosis of ovarian masses\nMiriam Lenhard1,*, Petra Stieber 2, Linda Hertlein 1,\nAngela Kirschenhofer1, Sophie Fu¨rst1, Doris Mayr 3,\nDorothea Nagel2, Karin Hofmann 2, Katja Krocker 2\nand Alexander Burges 1\n1 Department of Obstetrics and Gynecology, Ludwig-\nMaximilians-University Munich, Grosshadern Campus,\nMunich, Germany\n2 Institute for Clinical Chemistry, Ludwig-Maximilians-\nUniversity Munich, Grosshadern Campus, Munich,\nGermany\n3 Department of Pathology, Ludwig-Maximilians-University\nMunich, Munich, Germany\nAbstract\nBackground: Cancer antigen 125 (CA125) is the best\nknown single tumor marker for ovarian cancer (OC). We\ninvestigated whether the additional information of the human\nepididymis protein 4 (HE4) improves diagnostic accuracy.\nMethods: We retrospectively analyzed preoperative sera of\n109 healthy women, 285 patients with benign ovarian masses\n(cystadenoma: ns78, leimyoma: ns66, endometriosis: ns\n52, functional ovarian cysts: n s79, other: n s10), 16 low\nmalignant potential (LMP) ovarian tumors and 125 OC\n(stage I: 22, II: 15, III: 78, IV: 10). CA125 was analyzed\nusing the ARCHITECT system, HE4 using the ARCHI-\nTECT(a) system and EIA(e) technology additionally.\nResults: The lowest concentrations of CA125 and HE4 were\nobserved in healthy individuals, followed by patients with\nbenign adnexal masses and patients with LMP tumors and\nOC. The area under the curve (AUC) for the differential\ndiagnosis of adnexal masses of CA125 alone was not sig-\nnificantly different to HE4 alone in premenopausal (CA125:\n86.7, HE4(a): 82.6, HE4(e): 81.6% p)0.05) but significantly\ndifferent in postmenopausal wCA125: 93.4 vs. HE4(a): 88.3\nps0.023 and vs. HE4(e): 87.8% p s0.012x patients. For\nstage I OC, HE4 as a single marker was superior to CA125,\nwhich was the best single marker in stage II-IV . The com-\nbination of CA125 and HE4 using risk of malignancy algo-\nrithm (ROMA) gained the highest sensitivity at 95%\nspecificity for the differential diagnosis of adnexal masses\nwCA125: 70.9, HE4(a): 67.4, HE4(e): 66.0, ROMA(a): 76.6\n*Corresponding author: Miriam Lenhard, MD, Department of\nObstetrics and Gynecology, Ludwig-Maximilians-University\nMunich, Grosshadern Campus Marchioninistrasse 15, 81377\nMunich, Germany\nPhone: q49-89-7095-0, Fax: q49-89-7095-6724,\nE-mail: Miriam.Lenhard@med.uni-muenchen.de\nReceived April 18, 2011; accepted August 8, 2011;\npreviously published online September 16, 2011\nand ROMA(e): 74.5% x, especially in stage I OC wCA125:\n27.3, HE4(a): 40.9, HE4(e): 40.9, ROMA(a): 45.5 and\nROMA(e): 45.5%x.\nConclusions: CA125 is still the best single marker in the\ndiagnosis of OC. HE4 alone and even more the combined\nanalysis of CA125 and HE4 using ROMA improve the diag-\nnostic accuracy of adnexal masses, especially in early OC.\nKeywords: CA125; human epididymis protein 4 (HE4);\novarian cancer; risk of malignancy algorithm (ROMA);\ntumor marker.\nIntroduction\nOvarian cancer (OC) is the leading cause of death among\ngynecologic malignancies. Primary treatment includes oper-\native cytoreduction and subsequent platinum-based com-\nbined chemotherapy. Reported response rates to standard\nprimary treatment range around 80%, but 60%–70% of\npatients with OC relapse or die within 5 years after diagnosis\n(1–3). Due to the lack of diagnostic tools for early detection\nof OC, the vast majority of patients are detected at a pro-\ngressed stage of disease (4). Only 25%–30% of all OC\npatients are diagnosed at an early stage and have better sur-\nvival rates (5, 6). Persistent ovarian masses at subsequent\nvaginal sonographies are difficult to handle in clinical rou-\ntines. To rule out a malignant mass, operative exploration is\nfrequently recommended to the patient. Although most\nlesions turn out to be benign, some are OCs (7). The pro-\nportion of malignant ovarian tumors is higher in postmeno-\npausal in comparison to premenopausal women.\nBesides vaginal sonography, tumor marker values aid in\ndeciding which patients to operate on. Cancer antigen 125\n(CA125) as a single marker has been shown to be elevated\nin the majority of patients with OC. Moreover, its level is\nknown to be related to stage and histological type. Still, the\ndiagnosis and differential diagnosis remains difficult as 20%\nof all OC patients present with negative CA125 and a high\npercentage of patients with benign diseases show increased\ntumor marker values (8, 9). So far, the combination of\nCA125 and the human epididymis protein (HE4) measured\nby enzyme immunometric assay (EIA) technology (Fujirebio\nDiagnostics AB, Sweden) has been described to be of addi-\ntive value in the differential diagnosis of pelvic masses (10,\n11). The aim of this study was to assess whether the recently\ndeveloped automated test for HE4 on the ARCHITECT sys-\ntem (Abbott Diagnostics, USA) leads to comparable clinical\nresults in combination with CA125.\nBereitgestellt von | Universitaetsbibliothek der LMU Muenchen\nAngemeldet | 129.187.254.47\nHeruntergeladen am | 31.10.13 15:57\n\n2082 Lenhard et al.: Diagnostic accuracy of HE4 testing systems in ovarian cancer\nArticle in press - uncorrected proof\nMaterials and methods\nPatients\nWomen diagnosed and treated for low malignant potential (LMP)\ntumors of the ovary or OC between 1985 and 2008 were included\nin the study population. In the retrospective evaluation, tumor mark-\ner levels were analyzed with reference to patient characteristics and\nclinical data including menopausal status, histology or tumor stage.\nHealthy women and patients treated for benign ovarian masses\nserved as controls. The study was approved by the Local Ethical\nCommittee. Informed consent was obtained from all patients partic-\nipating in this study.\nSerum analysis\nAll serum samples had been obtained preoperatively at primary\ndiagnosis and had been stored at –80 8C. CA125 and HE4 were\nanalyzed in parallel using the ARCHITECT system wAbbott,\nARCHITECT, Abbott Park, IL, USA (a) x and using the EIA tech-\nnology (Fujirebio Diagnostics AB, Sweden, (e) x according to the\nmanufacturers’ instructions.\nThe ARCHITECT assay for HE4 and CA125 are both two-step\nimmunoassays. In the first step, sample and OC 125 coated or 2H5\nanti-HE4 coated paramagnetic microparticles were combined. OC\n125 defined antigen sample or HE4 antigen then bind to the OC\n125 coated or anti-HE4 coated microparticles. In the second step,\nM11 acridinium-labeled conjugate was added after washing in the\nCA125 assay and 3D8 anti-HE4 acridinium labeled conjugate in the\nHE4 assay. Chemilumniscent reaction was measured by relative\nlight units and directly reflects CA125 and HE4 concentrations in\nthe serum samples.\nThe HE4 EIA is a solid-phase, non-competitive immunoassay\nusing the same 2H5 and 3D8 antibodies as described for the\nARCHITECT assay. In short, samples are incubated with biotiny-\nlated anti-HE4 monoclonal antibody (MAb) 2H5 in streptavidin\ncoated microstrips. After washing incubation with HRP , labeled\nanti-HE4 MAb 3D8 was performed. Color intensity was measured\nto calculate HE4 serum concentration.\nMenopausal stage was defined according to follicle-stimulating\nhormone level concentrations measured. To assess the diagnostic\nvalue of HE4 and CA125 in combination, the final ROMA was\nused as described elsewhere (11):\nPremenopausal patients:\nPredictive Index (PI) s–12.0 q2.38=LNwHE4xq0.0626=LN\nwCA125x\nPostmenopausal patients:\nPredictive Index (PI) s–8.09 q1.04=LNwHE4xq0.732=LN\nwCA125x\nRisk of malignancysexp(PI)/w1qexp(PI)x=100.\nHistology\nAll patients were operated on by experienced gynecological sur-\ngeons. Tumor typing and staging were performed by experienced\ngynecological pathologists according to the criteria of the Interna-\ntional Federation of Gynaecologists and Obstetricians (FIGO) and\nthe International Union against Cancer (IUCC). Histology, FIGO\nstage and tumor grade according to the World Health Organization\n(WHO) were recorded.\nStatistics\nStatistical analysis was performed using SAS V9.2 (SAS Institute\nInc., Cary NC, USA). Tumor marker results are given as median,\nrange and percentile. Differences between groups were evaluated\nusing the non-parametric Wilcoxon test (e.g., histological subtype)\nor the non-parametric Jonckheere-Terpstra test (e.g., tumor stage).\nThe Passing and Bablok regression was performed to test for the\nequality of measurements of the two different analytical HE4 tech-\nnologies (12). Moreover, the Spearman correlation coefficient was\ncalculated for the values obtained with the HE4 EIA and HE4\nARCHITECT systems.\nThe AUCs were determined to reflect the relationship between\nsensitivity and specificity for single tumor markers or tumor marker\ncombinations. To compare AUCs for statistical significance, p-val-\nues were calculated (13). Sensitivities were also calculated at set\nspecificities of 75%, 90% and 95% for each marker and marker com-\nbinations. p-Values of-0.05 were regarded as statistically significant.\nResults\nPatient characteristics\nWe retrospectively analyzed preoperative sera of 109 healthy\nwomen, 285 patients with benign ovarian masses, 16 LMP\ntumors of the ovary and 125 OC. Patient’s characteristics\nincluding median age, menopausal status, histology, stage\nand grade are shown in detail in Table 1.\nTumor marker values\nThe Passing and Bablok regression analysis indicated com-\nparable results for the two HE4 technologies (all values:\nP/B regression HE4(a) s1.024=HE4(e)q6.030; n s646).\nThere was a good correlation between HE4 EIA and HE4\nARCHITECT measurement (Spearman: rs0.91) (Figure 1).\nThe lowest median concentrations of CA125 and HE4\nwere observed in healthy individuals, followed by patients\nwith benign disorders and patients presenting with LMP\ntumors. The highest marker concentrations were observed in\nOC patients. For each sub-group, the two HE4 technologies\nshowed similar values within the group (Table 2).\nFor the histological type, CA125 showed the highest\nserum concentrations in serous OC patients. In general, HE4\nmeasured by ARCHITECT and EIA showed comparable\nresults within each histological group of OC patients. The\nhighest median HE4 release was found for serous OCs, fol-\nlowed by endometrioid tumors. Significantly different mark-\ner levels between histological subtypes were observed\nbetween serous and mucinous OC in CA125 (ps0.0011) and\nHE4 ARCHITECT (p s0.0029) as well as HE4 EIA\n(ps0.0026) and also comparing serous to endometrioid OC\nin CA125 levels (p s0.0063) (Table 2).\nWith regard to tumor stage, the lowest median tumor\nmarker values were found in patients with stage I OC. Sig-\nnificant different tumor marker levels with regard to tumor\nstage were observed for CA125 (p -0.001), HE4 ARCHI-\nTECT (p-0.0098) and HE4 EIA (p -0.0089). Again, the\nserum testing for HE4 with the ARCHITECT or EIA tech-\nnology showed comparable results within each group of\npatients (Table 3).\nROC curves were calculated for the comparison of\npatients with benign ovarian masses vs. OC and LMP tumor\nBereitgestellt von | Universitaetsbibliothek der LMU Muenchen\nAngemeldet | 129.187.254.47\nHeruntergeladen am | 31.10.13 15:57\n\nLenhard et al.: Diagnostic accuracy of HE4 testing systems in ovarian cancer 2083\nArticle in press - uncorrected proof\nTable 1 Patients’ characteristics for healthy women, patients with benign ovarian masses, LMP or OC including median age, menopausal\nstatus, histology, stage and grade.\nPatients Number (n) Median age Menopausal Histology (n) Stage Grade\n(range) status (n) (FIGO)\nHealthy 109 38.4 (21.5–80.0) Premenopausal: 81\nwomen Postmenopausal: 20\nNA: 8\nBenign 285 44.6 (18.5–87.3) Premenopausal: 160 Cystadenoma: 78\novarian Postmenopausal: 125 Leiomyoma: 66\nmass Endometriosis: 52\nFunctional ovarian cyst: 79\nInflamm. adnexal disease: 3\nTeratoma: 7\nLMP 16 59.7 (23.6–88.3) Premenopausal: 3 Endometrioid: 1 I: 15 G2: 2\nPostmenopausal: 13 Mucinous: 7 II: 0 NA: 14\nSerous: 8 III: 1\nOC 125 62.9 (22.7–88.2) Premenopausal: 27 Endometroid: 12 I: 22 G1: 8\nPostmenopausal: 98 Mucinous: 8 II: 15 G2: 30\nSerous: 84 III: 78 G3: 68\nOther: 21 IV: 10 NA: 19\nFigure 1 The Passing and Bablok regression for the two HE4\ntechnologies (all values: P/B regression Y s1.024=Xq6.030;\nns646; Spearman: rs0.91).\npatients for the single marker HE4(a), HE4(e) and CA125\nas well as ROMA using either HE4(a) or HE4(e) (Table 4).\nThe combined analysis of CA125 and HE4 (ROMA), either\nwith the ARCHITECT or EIA, was significantly superior to\nboth HE4 tests alone wHE4(e) vs. ROMA(e) p s0.008,\nHE4(a) vs. ROMA(a) p s0.013x. No significant differences\nwere observed between the ROC curves for CA125 in com-\nparison to HE4 or ROMA using both HE4 technologies\nwCA125 vs. HE4(e) or vs. HE4(a) p )0.05, CA125 vs.\nROMA(e) or vs. ROMA(a) p )0.05x. Moreover, there were\nno significant differences between both HE4 testing systems\nand between both ROMA results wHE4(e) vs. HE4(a) p )\n0.05, ROMA(e) vs. ROMA(a) p )0.05x (Figure 2).\nAt a set specificity of 95%, sensitivities were lowest for\nall single markers or the marker combinations at premeno-\npausal status. When comparing single markers and ROMA\nin premenopausal patients, the AUCs of CA125, HE4(e) and\nHE4(a) and both ROMA were not significantly different\n(p)0.05 each).\nHowever, AUCs for both ROMA and both HE4 were sig-\nnificantly different in comparison to CA125 alone in post-\nmenopausal patients wCA125 vs. HE4(a) p s0.023, CA125\nvs. HE4(e) p s0.012, CA125 vs. ROMA(a) p s0.001,\nCA125 vs. ROMA(e) p s0.001 (Table 4)x.\nTable 5 shows the results for the comparison of patients\nwith a benign ovarian mass vs. patients with OC for different\ntumor stages. Sensitivities were calculated at set specificities\nof 75%, 90% and 95%, respectively. When raising specific-\nity, the highest loss in sensitivity is generally found in early\nstage disease. However, the combination of both ROMA\ngained the highest sensitivity at 95% specificity for stage I\nOC patients, followed by HE4 alone and CA125 alone. Only\nat stage I OC, CA125 seems to be inferior to both HE4 and\nboth ROMA (Table 5).\nDiscussion\nOC is often detected at progressed stage and ranks as the\nfifth most common cause of death in women (14). So far,\ndata for OC screening with vaginal sonography, clinical\nexamination and tumor marker evaluation are not satisfactory\n(15, 16). Moreover, the interpretation of tumor marker ele-\nvation remains difficult for the known variation in tumor\nmarker release due to inflammation, endometriosis, liver dis-\nease, ovulation or menopausal status (17, 18), which we\ncould also observe in our patient population.\nTumor marker CA125\nThere have been numerous studies describing preoperative\nCA125 in OC patients and few studies for ovarian borderline\nBereitgestellt von | Universitaetsbibliothek der LMU Muenchen\nAngemeldet | 129.187.254.47\nHeruntergeladen am | 31.10.13 15:57\n\n2084 Lenhard et al.: Diagnostic accuracy of HE4 testing systems in ovarian cancer\nArticle in press - uncorrected proof\nTable 2 CA125 and HE4 (ARCHITECT and EIA) concentrations for healthy women, patients with benign ovarian masses, patients\ndiagnosed with LMP tumor or OC showing median, range, 5th and 95th percentile (Pctl). In addition, CA125 and HE4 (ARCHITECT and\nEIA) concentrations are shown in detail for the histological subtypes. Significantly different results were observed between serous and\nmucinous OC in CA125 (p s0.0011), HE4 ARCHITECT (p s0.0029) and HE4 EIA (p s0.0026) and comparing serous to endometrioid\nOC in CA125 (p s0.0063).\nGroup n Marker Unit Median Range 5th Pctl 95th Pctl\nHealthy women 109 CA 125 ARCHITECT U/mL 13.5 4.0–49.7 7.4 30.0\nHE4 ARCHITECT pmol 40.4 4.5–111 15.2 72.0\nHE4 EIA pmol 32.5 2.5–444 2.5 77.2\nBenign ovarian mass 285 CA 125 ARCHITECT U/mL 19.6 4.0–276 8.4 124\nHE4 ARCHITECT pmol 40.3 18.8–1178 25.0 94.6\nHE4 EIA pmol 35.3 2.5–1120 2.5 96.7\nLMP 16 CA 125 ARCHITECT U/mL 34.7 18.1–385 18.1 335\nHE4 ARCHITECT pmol 52.1 28.2–399 28.2 399\nHE4 EIA pmol 43.7 13.6–441 13.6 441\nOC 125 CA 125 ARCHITECT U/mL 391 12.5–35813 28.3 7075\nAll HE4 ARCHITECT pmol 242 29.0–7507 37.7 2954\nHE4 EIA pmol 246 9.6–5669 33.8 3357\nSerous 84 CA 125 ARCHITECT U/mL 656.5 16.2–35813 39.4 3321\nHE4 ARCHITECT pmol 386.0 31.6–7507 54.2 3124\nHE4 EIA pmol 364.0 17.2–5669 40.8 3398\nMucinous 8 CA 125 ARCHITECT U/mL 126.5 29.2–285 29.2 285\nHE4 ARCHITECT pmol 74.1 35.4–147 35.4 447\nHE4 EIA pmol 75.6 33.8–335 33.8 335\nEndometrioid 12 CA 125 ARCHITECT U/mL 70.3 21.3–1749 21.3 1749\nHE4 ARCHITECT pmol 165.5 39.7–3469 39.7 3469\nHE4 EIA pmol 146.0 33.7–3357 33.7 3357\nOther 21 CA 125 ARCHITECT U/mL 211.0 12.5–13804 20.3 1564\nHE4 ARCHITECT pmol 161.0 29.0–2301 33.0 1134\nHE4 EIA pmol 146.0 9.6–1901 31.7 1202\nTable 3 CA125 and HE4 (ARCHITECT and EIA) concentrations in OC patients, detailed for tumor stage I-IV , showing median, range,\n5th and 95th percentile (Pctl). Significant differences between stages were observed for CA125 (two sided p -0.001), HE4 ARCHITECT\n(two sided p-0.0098) and HE4 EIA (two sided p -0.0089).\nGroup n Marker Unit Median Range 5th Pctl 95th Pctl\nAll OC 125 CA125 U/mL 391 12.5–35813 28.3 7075\nARCHITECT pmol 242 29.0–7507 37.7 2954\nHE4 ARCHITECT pmol 246 9.6–5669 33.8 3357\nHE4 EIA\nFIGO I 22 CA125 U/mL 38.2 12.5–1564 16.2 1459\nARCHITECT pmol 66.0 29.0–2301 33.0 1134\nHE4 ARCHITECT pmol 71.3 9.6–1901 31.7 1100\nHE4 EIA\nFIGO II 15 CA125 U/mL 1519 34.6–5855 34.6 5855\nARCHITECT pmol 538 53.2–7507 53.2 7507\nHE4 ARCHITECT pmol 624 43.8–5633 43.8 5633\nHE4 EIA\nFIGO III 78 CA125 U/mL 505 28.5–35813 56.2 9227\nARCHITECT pmol 340 33.2–5184 50.5 3124\nHE4 ARCHITECT pmol 317 32.1–5669 35.8 3398\nHE4 EIA\nFIGO IV 10 CA125 U/mL 559 28.3–8323 28.3 8323\nARCHITECT pmol 300 31.6–1114 31.6 1114\nHE4 ARCHITECT pmol 341 17.2–1076 17.2 1076\nHE4 EIA\npatients (19–21). OC patients, but also ovarian borderline\ntumor patients are known to present with elevated CA125 in\nmost cases (21, 22). Our data confirm that serum CA125 in\nOC patients differ in median from healthy controls, patients\nwith benign gynecologic disease and patients with ovarian\nborderline tumors. Patients with OC generally show the high-\nBereitgestellt von | Universitaetsbibliothek der LMU Muenchen\nAngemeldet | 129.187.254.47\nHeruntergeladen am | 31.10.13 15:57\n\nLenhard et al.: Diagnostic accuracy of HE4 testing systems in ovarian cancer 2085\nArticle in press - uncorrected proof\nFigure 2 ROC curves for CA125, HE4 wEIA and ARCHI-\nTECT(a)x and ROMA using either the HE4 EIA or ARCHITECT(a)\ntechnology.\nDiagnostic accuracy is calculated for patients with benign ovarian\nmass vs. all OC patients and patients with LMP tumors.\nest levels of CA125, healthy women the lowest levels. More-\nover, patients with progressed OC present with higher tumor\nmarker values, which was also described in literature (23).\nMedian tumor marker values differ in patients with various\nhistological subtypes of OC. Our data show serous OC\npatients to have the highest CA125 concentrations in median,\nwhich agrees with the data of other centers (23, 24).\nTumor marker HE4\nCA125 is the most commonly used tumor marker in the diag-\nnosis and differential diagnosis of pelvic masses (10, 11).\nNew tumor markers like HE4 are gaining importance. Drap-\nkin et al. showed that HE4 is distributed in a region of the\ncytoplasm with a perinuclear pattern reminiscent of the\nendoplasmic reticulum and the Golgi apparatus (24). The\nHE4 gene encodes a protease inhibitor with a role in protec-\ntive immunity and is primarily expressed in the reproductive\ntract and upper airways (24, 25). Moreover, the HE4 gene\nproduct is N-glycosylated and secreted into the extracellular\nenvironment of cancer cells, and elevated serum levels can\nbe measured in these patients. Some studies analyzed HE4\nin gynecological cancer patients (26). We concentrated on\nOC and ovarian borderline tumor patients with appropriate\ncontrol groups of gynecological patients and healthy women\nand compared the results of two different HE4 measurement\nsystems. Tumor marker values for HE4 were lowest in stage\nI disease with both technologies used. The data agrees with\nthe results published by Montagnana et al. (10), who also\nfound a stage dependent HE4 release in OC. Interestingly,\nHE4 was more frequently expressed in early stage disease\nwhen compared to CA125. Especially at very high specific-\nity, HE4 alone achieves 40.9% sensitivity with both HE4\ntechniques. In comparison to single HE4 values, CA125\nalone only has a sensitivity of 27.3% and is therefore inferior\nto HE4 testing. Especially at early stage disease, HE4 seems\nto improve the identification of OC patients. Our results are\nin accordance with the data published by Havrilesky et al. (27).\nSimilar to CA125, HE4 shows the highest tumor marker\nvalues for serous OC patients, which is also in agreement\nwith data in literature (10). Interestingly, HE4 levels are also\nrelatively high in patients with endometrioid tumors. We\nrecently found HE4 to be less frequently elevated in benign\ngynecological disease (data not presented in detail for dif-\nferent diseases here) like endometriosis, where CA125 can\nattain relatively high serum values. Still, there are diseases\nin which HE4 also lacks specificity, like inflammation or\nrenal failure (28). Moreover, recent data describe a signifi-\ncant variation of HE4 release in healthy women under the\nage of 35, which depends on the female hormonal cycle.\nTherefore, Anastasi et al. point out that it is necessary to\nproperly interpret HE4 data with regard to the female hor-\nmonal cycle (29).\nMarker combination\nVarious studies investigated the use of tumor marker com-\nbinations in OC patients (11, 27, 30–37). The combination\nof CA125 and HE4 seems to be favorable in most studies\nfor the differential diagnosis of these patients (31, 34).\nMoore et al. used the dual marker combination of HE4 and\nCA125 in ROMA to classify women into high and low risk\ngroups (11).\nIn this study, we assessed whether the automated test for\nHE4 with the ARCHITECT system and the manual HE4 EIA\nlead to comparable clinical results in combination with CA125.\nThe results achieved with the dual marker combination\nand information on the patient’s menopausal status, as per-\nformed in ROMA, are comparable to the published result of\nthe most commonly used risk of malignancy index (RMI)\n(38–40), RMI utilizes a combination of serum CA125 val-\nues, pelvic sonography and the menopausal status (41). In\nJacobs et al. a sensitivity of 95.1% is noted at 76.5% spec-\nificity (42). In a recently published study, Moore et al. com-\npared the RMI with ROMA (43). At a set specificity of 75%,\nROMA had a sensitivity of 94.3% and RMI had a sensitivity\nof 84.6% for distinguishing benign findings from EOC (43).\nFurther analysis for patients with early stage disease showed\na sensitivity of 85.3% for ROMA compared to 64.7% for\nRMI. The authors therefore concluded that the dual marker\nalgorithm utilizing HE4 and CA125 achieves a higher sen-\nsitivity than RMI in the diagnosis of OC (43).\nA recently published study by Montagnana et al. con-\ncludes ROMA to be excellent in the detection of OC of post-\nmenopausal but not premenopausal women (30). This\nfinding goes along with our results as we observed AUCs of\n83.1% with ROMA using the ARCHITECT and 82.0% using\nthe EIA technology in premenopausal women in comparison\nto 93.9% (ARCHITECT) and 93.2% (EIA) in postmenopau-\nBereitgestellt von | Universitaetsbibliothek der LMU Muenchen\nAngemeldet | 129.187.254.47\nHeruntergeladen am | 31.10.13 15:57\n\n2086 Lenhard et al.: Diagnostic accuracy of HE4 testing systems in ovarian cancer\nArticle in press - uncorrected proof\nTable 4 Sensitivity at 95% specificity and AUC values with lower confidence limits (LCL) and upper confidence limits (UCL) in the\ndifferentiation of benign and malignant gynecological masses for CA125, HE4 ARCHITECT, HE4 EIA and ROMA using the HE4 ARCHI-\nTECT and HE4 EIA system. Results are also shown in detail by menopausal status.\nPatients Marker Sensitivity at AUC %\n95% specificity (LCL–UCL)\nAll patients: CA 125 ARCHITECT 70.9% 91.1 (88.2–94.0)\nbenign ovarian mass HE4 ARCHITECT 67.4% 89.0 (85.4–92.7)\n(ns285) vs. OCqLMP (ns141) HE4 EIA 66.0% 88.2 (84.5–91.9)\nROMA (HE4 ARCHITECT) 76.6% 92.4 (89.3–95.6)\nROMA (HE4 EIA) 74.5% 91.8 (88.6–95.0)\nPremenopausal patients: CA 125 ARCHITECT 60.0% 86.7 (78.8–94.5)\nbenign ovarian mass HE4 ARCHITECT 66.7% 82.6 (72.1–93.5)\n(ns160) vs. OCqLMP (ns30) HE4 EIA 56.7% 81.6 (71.1–92.0)\nROMA (HE4 ARCHITECT) 66.6% 83.1 (72.6–93.7)\nROMA (HE4 EIA) 56.7% 82.0 (71.7–92.3)\npostmenopausal patients: CA 125 ARCHITECT 73.0% 93.4 (90.6–96.3)\nbenign ovarian mass HE4 ARCHITECT 66.8% 88.3 (84.0–92.7)\n(ns125) vs. OCqLMP (ns111) HE4 EIA 64.9% 87.8 (83.4–92.2)\nROMA (HE4 ARCHITECT) 72.1% 93.9 (91.1–96.7)\nROMA HE4 EIA) 71.2% 93.2 (90.2–96.3)\nTable 5 Tumor marker sensitivity at set specificity of 75%, 90% and 95% for CA125, HE4 ARCHITECT, HE4 EIA, ROMA using the\nHE4 ARCHITECT and ROMA using the HE4 EIA, detailed for tumor stage I–IV .\nBenign Marker Sensitivity at Sensitivity at Sensitivity at\novarian mass 75% specificity 90% specificity 95% specificity\n(ns285) vs.\nOC CA125 ARCHITECT 50.0% 27.3% 27.3%\nFIGO I HE4 ARCHITECT 68.2% 45.5% 40.9%\n(ns22) HE4 EIA 63.6% 50.0% 40.9%\nROMA (HE4 ARCHITECT) 86.4% 59.1% 45.5%\nROMA (HE4 EIA) 81.8% 59.1% 45.5%\nOC CA 125 ARCHITECT 93.3% 86.7% 86.7%\nFIGO II HE4 ARCHITECT 100% 80.0% 80.0%\n(ns15) HE4 EIA 100% 80.0% 80.0%\nROMA (HE4 ARCHITECT) 93.3% 86.7% 86.7%\nROMA (HE4 EIA) 93.3% 86.7% 80.0%\nOC CA125 ARCHITECT 98.7% 92.3% 89.7%\nFIGO III HE4 ARCHITECT 94.9% 88.5% 83.3%\n(ns78) HE4 EIA 92.3% 85.9% 80.8%\nROMA (HE4 ARCHITECT) 98.7% 96.2% 92.3%\nROMA (HE4 EIA) 98.7% 93.6% 89.7%\nOC CA125 ARCHITECT 90.0% 80.0% 80.0%\nFIGO IV HE4 ARCHITECT 80.0% 80.0% 70.0%\n(ns10) HE4 EIA 80.0% 70.0% 70.0%\nROMA (HE4 ARCHITECT) 80.0% 80.0% 80.0%\nROMA (HE4 EIA) 80.0% 80.0% 80.0%\nsal women. This variability should always be taken into\naccount when ROMA score results are compared (30).\nStill, results on CA125, HE4 and ROMA are partly con-\ntroversial. Ruggeri et al. found HE4 to be more specific and\naccurate than CA125 (34), whereas Van Gorg et al. conclud-\ned HE4 and ROMA not to increase the detection of ovarian\ncancer (37). Jacob et al. analyzed HE4 and CA125 with or\nwithout ROMA and RMI and concluded not to see a benefit\nfrom combining HE4 and CA125 as tumor markers in a clin-\nical setting (36).\nWe observed the highest benefit for HE4 and ROMA in\nOC patients and early stage disease. This finding was also\ndescribed by others (11, 36).\nAltogether, the differences in CA125, HE4 and ROMA\nresults may be attributable to various numbers of patients,\ntumor stages, menopausal status or histologic subtypes in the\novarian cancer patient study groups and also control groups.\nStrengths of this study are the large patient and control\ngroups, the persistent high standard of surgery by gyneco-\nlogic oncologists at a specialized academic institution and\nBereitgestellt von | Universitaetsbibliothek der LMU Muenchen\nAngemeldet | 129.187.254.47\nHeruntergeladen am | 31.10.13 15:57\n\nLenhard et al.: Diagnostic accuracy of HE4 testing systems in ovarian cancer 2087\nArticle in press - uncorrected proof\nthe consistent histopathologic review by expert gynecologic\noncology pathologists.\nConclusions\nIn the differential diagnosis of OC patients, CA125 still rep-\nresents the best single tumor marker. The combined analysis\nof CA125 and HE4, using either the ARCHITECT or EIA\nsystem, improves the diagnostic accuracy in the distinction\nof ovarian tumors, especially in early OC. Both HE4 testing\nmethods can be used in clinical routines since the HE4\nARCHITECT shows comparable results with the HE4 EIA\ntechnology.\nAcknowledgments\nWe thank Dr. Barry Dowell and Sabrina Chan (Abbott Diagnostics,\nUSA) und Dr. Olle Nilsson (Fujirebio Diagnostics, Sweden) for\ntheir support with reagents and equipment and for contributing their\nscientific know how in data evaluation and discussion.\nConflict of interest statement\nAuthors’ conflict of interest disclosure: The authors stated that\nthere are no conflicts of interest regarding the publication of this\narticle.\nResearch funding: None declared.\nEmployment or leadership: None declared.\nHonorarium: None declared.\nReferences\n1. Berek JS, Bertelsen K, du Bois A, Brady MF , Carmichael J,\nEisenhauer EA, et al. Advanced epithelial ovarian cancer: 1998\nconsensus statements. Ann Oncol 1999;10:87–92.\n2. Omura GA, Brady MF , Homesley HD, Y ordan E, Major FJ,\nBuchsbaum HJ, et al. Long-term follow-up and prognostic factor\nanalysis in advanced ovarian carcinoma: the Gynecologic Oncol-\nogy Group experience. J Clin Oncol 1991;9:1138–50.\n3. Thigpen JT, Bertelsen K, Eisenhauer EA, Hacker NF , Lund B,\nSessa C. Long-term follow-up of patients with advanced ovarian\ncarcinoma treated with chemotherapy. Ann Oncol 1993;4:35–\n40.\n4. Cannistra SA. Cancer of the ovary. N Engl J Med 1993;329:\n1550–9.\n5. Chan J, Fuh K, Shin J, Cheung M, Powell C, Chen LM, et al.\nThe treatment and outcomes of early-stage epithelial ovarian can-\ncer: have we made any progress? Br J Cancer 2008;98:1191–6.\n6. Lenhard SM, Bufe A, Kumper C, Stieber P , Mayr D, Hertlein L,\net al. Relapse and survival in early-stage ovarian cancer. Arch\nGynecol Obstet 2009;280:71–7.\n7. Fishman DA, Cohen L, Blank SV , Shulman L, Singh D, Bozorgi\nK, et al. The role of ultrasound evaluation in the detection of\nearly-stage epithelial ovarian cancer. Am J Obstet Gynecol\n2005;192:1214–21.\n8. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus\nH, et al. A radioimmunoassay using a monoclonal antibody to\nmonitor the course of epithelial ovarian cancer. N Engl J Med\n1983;309:883–7.\n9. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen:\na review of the literature. Hum Reprod 1989;4:1–12.\n10. Montagnana M, Lippi G, Ruzzenente O, Bresciani V , Danese\nE, Scevarolli S, et al. The utility of serum human epididymis\nprotein 4 (HE4) in patients with a pelvic mass. J Clin Lab Anal\n2009;2:331–5.\n11. Moore RG, McMeekin DS, Brown AK, DiSilvestro P , Miller\nMC, Allard WJ, et al. A novel multiple marker bioassay util-\nizing HE4 and CA125 for the prediction of ovarian cancer in\npatients with a pelvic mass. Gynecol Oncol 2009;112:40–6.\n12. Passing H, Bablok W . A new biometrical procedure for testing\nthe equality of measurements from two different analytical\nmethods. Application of linear regression procedures for meth-\nod comparison studies in clinical chemistry, Part I. J Clin Chem\nClin Biochem 1983;21:709–20.\n13. Hanley JA, McNeil BJ. A method of comparing the areas under\nreceiver operating characteristic curves derived from the same\ncases. Radiology 1983;148:839–43.\n14. Heintz AP , Odicino F , Maisonneuve P , Quinn MA, Benedet JL,\nCreasman WT, et al. Carcinoma of the ovary. FIGO 6th Annual\nReport on the Results of Treatment in Gynecological Cancer.\nInt J Gynaecol Obstet 2006;95:S161–92.\n15. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M,\nSharma A, et al. Sensitivity and specificity of multimodal and\nultrasound screening for ovarian cancer, and stage distribution\nof detected cancers: results of the prevalence screen of the UK\nCollaborative Trial of Ovarian Cancer Screening (UKCTOCS).\nLancet Oncol 2009;10:327–40.\n16. Joyner AB, Runowicz CD. Ovarian cancer screening and early\ndetection. Womens Health (Lond Engl) 2009;5:693–9.\n17. Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC. Accuracy\nof CA 125 in the diagnosis of ovarian tumors: a quantitative\nsystematic review. Eur J Obstet Gynecol Reprod Biol 2009;\n142:99–105.\n18. Kenemans P , Yedema CA, Bon GG, von Mensdorff-Pouilly S.\nCA 125 in gynecological pathology – a review. Eur J Obstet\nGynecol Reprod Biol 1993;49:115–24.\n19. Gotlieb WH, Soriano D, Achiron R, Zalel Y, Davidson B,\nKopolovic J, et al. CA 125 measurement and ultrasonography\nin borderline tumors of the ovary. Am J Obstet Gynecol\n2000;183:541–6.\n20. van Nagell JR Jr, DePriest PD, Ueland FR, DeSimone CP , Coo-\nper AL, McDonald JM, et al. Ovarian cancer screening with\nannual transvaginal sonography: findings of 25,000 women\nscreened. Cancer 2007;109:1887–96.\n21. Lenhard MS, Nehring S, Nagel D, Mayr D, Kirschenhofer A,\nHertlein L, et al. Predictive value of CA 125 and CA 72-4 in\novarian borderline tumors. Clin Chem Lab Med 2009;47:\n537–42.\n22. Zurawski VR Jr, Orjaseter H, Andersen A, Jellum E. Elevated\nserum CA 125 levels prior to diagnosis of ovarian neoplasia:\nrelevance for early detection of ovarian cancer. Int J Cancer\n1988;42:677–80.\n23. Y oung RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks\nGD, Decker DG, et al. Adjuvant therapy in stage I and stage\nII epithelial ovarian cancer. Results of two prospective random-\nized trials. N Engl J Med 1990;322:1021–7.\n24. Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP , Welch\nWR, et al. Human epididymis protein 4 (HE4) is a secreted\nglycoprotein that is overexpressed by serous and endometrioid\novarian carcinomas. Cancer Res 2005;65:2162–9.\n25. Bouchard D, Morisset D, Bourbonnais Y, Tremblay GM. Pro-\nBereitgestellt von | Universitaetsbibliothek der LMU Muenchen\nAngemeldet | 129.187.254.47\nHeruntergeladen am | 31.10.13 15:57\n\n2088 Lenhard et al.: Diagnostic accuracy of HE4 testing systems in ovarian cancer\nArticle in press - uncorrected proof\nteins with whey-acidic-protein motifs and cancer. Lancet Oncol\n2006;7:167–74.\n26. Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard\nWJ, et al. Utility of a novel serum tumor biomarker HE4 in\npatients with endometrioid adenocarcinoma of the uterus.\nGynecol Oncol 2008;110:196–201.\n27. Havrilesky LJ, Whitehead CM, Rubatt JM, Cheek RL, Groelke\nJ, He Q, et al. Evaluation of biomarker panels for early stage\novarian cancer detection and monitoring for disease recurrence.\nGynecol Oncol 2008;110:374–82.\n28. Dong L, Chang XH, Ye X, Zhu LR, Zhao Y, Tian L, et al. The\nvalues of serum human epididymis secretory protein 4 and\nCA(125) assay in the diagnosis of ovarian malignancy. Zhong-\nhua Fu Chan Ke Za Zhi 2008;43:931–6.\n29. Anastasi E, Granato T, Marchei GG, Viggiani V , Colaprisca B,\nComploj S, et al. Ovarian tumor marker HE4 is differently\nexpressed during the phases of the menstrual cycle in healthy\nyoung women. Tumour Biol 2010;31:411–5.\n30. Montagnana M, Danese E, Ruzzenente O, Bresciani V , Nuzzo\nT, Gelati M, et al. The ROMA (Risk of Ovarian Malignancy\nAlgorithm) for estimating the risk of epithelial ovarian cancer\nin women presenting with pelvic mass: is it really useful? Clin\nChem Lab Med 2011;49:521–5.\n31. Kim YM, Whang DH, Park J, Kim SH, Lee SW , Park HA, et\nal. Evaluation of the accuracy of serum human epididymis pro-\ntein 4 in combination with CA125 for detecting ovarian cancer:\na prospective case-control study in a Korean population. Clin\nChem Lab Med 2011;49:527–34.\n32. Bast RC Jr., Badgwell D, Lu Z, Marquez R, Rosen D, Liu J,\net al. New tumor markers: CA125 and beyond. Int J Gynecol\nCancer 2005;15:274–81.\n33. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch\nT, et al. The use of multiple novel tumor biomarkers for the\ndetection of ovarian carcinoma in patients with a pelvic mass.\nGynecol Oncol 2008;108:402–8.\n34. Ruggeri G, Bandiera E, Zanotti L, Belloli S, Ravaggi A, Roma-\nni C, et al. HE4 and epithelial ovarian cancer: Comparison and\nclinical evaluation of two immunoassays and a combination\nalgorithm. Clin Chim Acta 2011;412:1447–53.\n35. Park Y, Kim Y, Lee EY, Lee JH, Kim HS. Reference ranges\nfor HE4 and CA125 in a large Asian population by automated\nassays and diagnostic performances for ovarian cancer. Int J\nCancer 2011. April 11. doi: 10.1002/ijc.26129 wEpub ahead of\nprintx.\n36. Jacob F , Meier M, Caduff R, Goldstein D, Pochechueva T,\nHacker N, et al. No benefit from combining HE4 and CA125\nas ovarian tumor markers in a clinical setting. Gynecol Oncol\n2011;121:487–91.\n37. Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K,\nAmant F , et al. HE4 and CA125 as a diagnostic test in ovarian\ncancer: prospective validation of the Risk of Ovarian Malig-\nnancy Algorithm. Br J Cancer 2011;104:863–70.\n38. McDonald JM, Doran S, DeSimone CP , Ueland FR, DePriest\nPD, Ware RA, et al. Predicting risk of malignancy in adnexal\nmasses. Obstet Gynecol 2010;115:687–94.\n39. Kader Ali Mohan GR, Jaaback K, Proietto A, Robertson R,\nAngstetra D. Risk Malignancy Index (RMI) in patients with\nabnormal pelvic mass: Comparing RMI 1, 2 and 3 in an Aus-\ntralian population. Aust N Z J Obstet Gynaecol 2010;50:77–80.\n40. van den Akker PA, Aalders AL, Snijders MP , Kluivers KB,\nSamlal RA, Vollebergh JH, et al. Evaluation of the Risk of\nMalignancy Index in daily clinical management of adnexal\nmasses. Gynecol Oncol 2010;116:384–8.\n41. Moolthiya W , Yuenyao P . The risk of malignancy index (RMI)\nin diagnosis of ovarian malignancy. Asian Pac J Cancer Prev\n2009;10:865–8.\n42. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas\nJG. A risk of malignancy index incorporating CA 125, ultra-\nsound and menopausal status for the accurate preoperative diag-\nnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97:922–9.\n43. Moore RG, Jabre-Raughley M, Brown AK, Robison KM,\nMiller MC, Allard WJ, et al. Comparison of a novel multiple\nmarker assay vs. the Risk of Malignancy Index for the predic-\ntion of epithelial ovarian cancer in patients with a pelvic mass.\nAm J Obstet Gynecol 2010;203:228e1–6.\nBereitgestellt von | Universitaetsbibliothek der LMU Muenchen\nAngemeldet | 129.187.254.47\nHeruntergeladen am | 31.10.13 15:57","source_license":"CC0","license_restricted":false}